Finance & valuation

Latest content

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline

13 August 2020

The best way to value biotech for deal making and investments

Why analysts must look beyond traditional valuation methodologies to an alternative ‘real options’ framework

12 August 2020

Bypass covid-19 drug patents demand US state attorney generals

The pandemic has puts compulsory licensing firmly on the agenda in the country that is friendliest to life sciences IP owners

11 August 2020

Report: half of failed IPOs on Shanghai tech board sidelined for IP reasons

No fewer than 17 companies have had listing plans scuppered due to a variety of IP deficiencies

10 August 2020

Inside China's first top-down FRAND royalty decision

Exclusive analysis of the recently published full judgment of the Nanjing Intermediate People's Court in Huawei v Conversant

05 August 2020

Top patent owners continue to outperform the markets, according to new analysis

Publicly-quoted companies in the IAM/ktMINE US Patent 100 enjoyed a strong June compared to their peers

31 July 2020

China passes a major threshold in life sciences IP reform

Move to implement patent linkage is the clearest sign yet that the country is embracing pharma and biotech innovation

30 July 2020

Clarivate's acquisition of CPA Global raises plenty of questions

Deal creates an IP behomoth and continues the trend towards service provider consolidation - but the new company's clients will need reassurances

29 July 2020

Patent risk profile front and centre in run up to Ant Group’s IPO

The company’s filings have exploded since the second half of 2019 and, while it is difficult to discern the quality of the assets, the portfolio is in capable hands

24 July 2020

How to price the IP rights underpinning disruptive biotech innovation

Analysts must look beyond traditional valuation methodologies to an alternative real options framework if they are to get the most bang for their buck

23 July 2020

Get unlimited access to all IAM content